Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer
Ignace Vergote(KU Leuven), Peter G. Rose(Cleveland Clinic), James B. Hall(Levine Cancer Institute), James Keck(Jackson Laboratory), Marsha Jones, Robert P. Edwards(Cancer Research UK Technology), Lisa Meng(Cytokinetics (United States)), Gail L. Brown(Palo Alto Institute), Elaine M. Rankin(The Netherlands Cancer Institute), James J. Burke(Memorial Health University Medical Center), O.O. Melnyk(Bay Area Cancer Connections), Neil J. Finkler(Florida Hospital Cancer Institute), Ralph V. Boccia(Center for Cancer and Blood Disorders), Carolyn D. Runowicz(Florida International University)
Cited by 62
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
American Cancer Society Guidelines for the Early Detection of Cancer
|CA A Cancer Journal for Clinicians|2002|1.6k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
|New England Journal of Medicine|2007|1.1k
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
|Journal of Clinical Oncology|2015|1k